<DOC>
	<DOCNO>NCT00383565</DOCNO>
	<brief_summary>FR901228 may stop growth cancer cell block enzymes need cell grow block blood flow cancer . This phase II trial study well FR901228 work treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>FR901228 Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate ( complete partial ) FR901228 patient relapse refractory mantle cell diffuse large cell non-Hodgkin 's lymphoma . II . Evaluate safety feasibility FR901228 , term incidence toxicity maximum grade observe course delay dose reduction , patient . III . Determine 2-year progression-free overall survival . OUTLINE : Patients receive FR901228 IV 4 hour day 1 , 8 , 15 . Treatment repeat every 28 day least 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histologically confirm aggressive Bcell nonHodgkin 's lymphoma 1 follow subtypes : Mantle cell lymphoma Diffuse large cell lymphoma ( Ineligible unwilling undergo stem cell transplantation ) Relapsed refractory disease : Any number prior therapy allow relapsed disease , include peripheral blood stem cell bone marrow transplantation No 2 prior regimen , exclude monotherapy monoclonal antibody radiotherapy , refractory disease Measurable disease , define &gt; = 1 lesion &gt; = 1.5 cm long diameter No transform lymphoma , define transformation lowgrade lymphoma , include follicular lymphoma small lymphocytic lymphoma , highgrade lymphoma ( e.g. , diffuse large cell lymphoma ) ECOG performance status 02 Absolute neutrophil count &gt; = 1,000/mm^3 OR &gt; = 500/mm^3 extensive bone marrow involvement ( &gt; 50 % ) hypersplenism palpable splenomegaly Platelet count &gt; = 75,000/mm^3 OR &gt; = 50,000/mm^3 extensive bone marrow involvement ( &gt; 50 % ) hypersplenism palpable splenomegaly Bilirubin normal Alkaline phosphatase = &lt; 2 time upper limit normal ( ULN ) AST = &lt; 2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant cardiac disease , include New York Heart Association class IIIIV congestive heart failure No history serious ventricular arrhythmia QTc &lt; 500 msec No evidence cardiac hypertrophy ECG No known HIV positivity No uncontrolled serious medical condition active infection ( e.g. , chronic obstructive pulmonary disease , diabetes ) Recovered prior therapy No prior doxorubicin hydrochloride &gt; = 450 mg/m^2 mitoxantrone &gt; = 112 mg/m^2 ( Patients receive mitoxantrone doxorubicin hydrochloride `` doxorubicin equivalent dose '' &lt; 450 mg/m^2 No prior therapy histone deacetylase inhibitor No concurrent dexamethasone prednisone except refractory nausea/vomiting No concurrent drug associate QTc prolongation ( e.g. , dolasetron mesylate ) Concurrent hydrochlorothiazide , furosemide , diuretic allow provided patient receive potassium chloride supplementation ( No supplementation need switched potassiumconserving diuretic ) No CNS lymphoma Creatinine normal Cardiac function &gt; = 50 % MUGA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>